Macleods recalls Losartan lot for NDEA

Macleods Pharmaceuticals has recalled a batch of drugs for blood pressure and the heart, Losartan, on the presence of NDEA, joining the many companies who have recalled some of his drugs: Losartan, Valsartan or Irbesartan about his probable carcinogen.

Although the impurity N-nitrosodiethylamine (NDEA) appears naturally in many places, the International Agency for Research on Cancer terms it "likely carcinogenic to humans". However, even the FDA said in January that the increased risk of cancer resulting from taking Losartan, Valsartan or Irbesartan with too much NDEA is small.

Nevertheless, Macleods takes a batch of 100 mg / 25 mg tablets of combination of potassium and losartan hydrochlorothiazide in vials of 90 tablets containing more NDEA than the acceptable daily intake levels of the FDA. This is Lot No. BLM715A whose expiry date is July 2019. The drug was manufactured in India.

The Macleods Recall Notification tells patients the same as other companies' notifications: until you find an alternative treatment with your doctor or pharmacist, continue taking Losartan. If you stop, the risk of problems is greater.

Anyone with questions can contact Qualanex, who handles product returns for Macleods, by email at the address [email protected] or by phone at 888-280-2042, Monday through Friday, 8 am at 17 o'clock.